ELVN net incomeQ3 2026-$27.70M
ELVN net income was -$27.70M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$20.15M a year earlier. For the full fiscal 2025 it was -$103.69M, compared with -$89.02M in fiscal 2024.
Enliven Therapeutics Inc. (ELVN) financials
For the twelve months ended Sep 30, 2026, Enliven Therapeutics Inc. reported -$113.48M of net income.
- Net income, TTM
- -$113.48M
- Free cash flow, TTM
- -$66.41M
- EPS, diluted, TTM
- -$1.68
- Cash
- $151.67M
- Market cap
- $3.77B
FY2019FY2025
FY2019FY2025
ELVN revenue and earnings growth
ELVN EPSQ3 2026-$0.36
ELVN diluted EPS was -$0.36 in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$0.32 a year earlier. For the full fiscal 2025 it was -$1.83, compared with -$1.89 in fiscal 2024.
ELVN free cash flowQ3 2026-$12.65M
ELVN free cash flow was -$12.65M in fiscal Q3 2026 (ended Sep 30, 2026), compared with -$13.28M a year earlier. For the full fiscal 2025 it was -$70.46M, compared with -$73.24M in fiscal 2024.
Income statement
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Research and development | $85.86M | $80.78M | $64.57M | $31.02M | $38.44M | $32.15M | $19.01M |
| Selling, general and admin | $33.80M | $23.78M | $18.95M | $7.77M | $13.00M | $9.54M | $5.11M |
| Operating income | -$119.66M | -$104.55M | -$83.53M | -$38.79M | -$51.44M | -$41.70M | -$24.12M |
| Pre-tax income | - | - | - | $1.58M | -$51.38M | - | - |
| Income tax | $0 | $232.0K | $0 | $0 | - | - | - |
| Net income | -$103.69M | -$89.02M | -$71.58M | -$37.66M | -$51.38M | -$41.36M | -$23.46M |
| EPS, basic | -$1.83 | -$1.89 | -$2.01 | -$12.05 | -$2.37 | -$3.53 | -$33.40 |
| EPS, diluted | -$1.83 | -$1.89 | -$2.01 | -$12.05 | -$2.37 | -$3.53 | -$33.40 |
| Diluted shares | 56.7M | 47.1M | 35.5M | 3.1M | 21.7M | 13.9M | 702,455 |
Balance sheet
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Cash and equivalents | $98.90M | $124.17M | $100.19M | $75.59M | $110.08M | $47.79M | $5.02M |
| Short-term investments | $363.73M | $189.32M | $153.01M | $0 | - | - | - |
| Current assets | $474.88M | $318.13M | $266.15M | $77.75M | $92.70M | $90.41M | $30.62M |
| Total assets | $476.17M | $325.76M | $271.87M | $83.30M | $93.65M | $90.84M | $33.30M |
| Current liabilities | $16.57M | $15.91M | $25.89M | $9.71M | $7.21M | $6.25M | $4.20M |
| Total liabilities | $16.57M | $15.91M | $25.96M | $10.37M | $7.62M | $6.41M | $4.38M |
| Shareholders' equity | $459.60M | $309.85M | $245.91M | -$76.83M | -$42.89M | $84.44M | -$48.85M |
Cash flow
| Line item | Dec 31, 2025 | Dec 31, 2024 | Dec 31, 2023 | Dec 31, 2022 | Dec 31, 2021 | Dec 31, 2020 | Dec 31, 2019 |
|---|---|---|---|---|---|---|---|
| Operating cash flow | -$70.30M | -$73.19M | -$61.27M | -$32.08M | -$46.77M | -$37.40M | -$21.88M |
| Capital expenditures | $158.0K | $44.0K | $149.0K | $612.0K | $12.0K | $18.0K | $140.0K |
| Free cash flow | -$70.46M | -$73.24M | -$61.42M | -$32.69M | -$46.78M | -$37.42M | -$22.02M |
| Investing cash flow | -$173.84M | -$36.00M | -$148.41M | -$612.0K | -$1.63M | -$16.72M | -$24.06M |
| Financing cash flow | $218.87M | $133.16M | $234.29M | -$1.80M | $49.10M | $96.88M | $43.58M |
| Stock-based compensation | $34.02M | $20.17M | $12.91M | $3.19M | $3.85M | $2.23M | $899.0K |
| Depreciation and amortization | $300.0K | $300.0K | $300.0K | $200.0K | - | - | - |
Key ratios
Income statement
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Research and development | $28.02M | $29.00M | $20.69M | $21.25M | $18.23M | $21.49M | $24.89M | $20.72M | $21.26M | $18.83M | $19.97M | $17.91M |
| Selling, general and admin | $8.02M | $8.21M | $7.14M | $13.04M | $6.87M | $7.09M | $6.80M | $6.17M | $5.81M | $5.78M | $6.02M | $4.82M |
| Operating income | -$36.05M | -$37.21M | -$27.82M | -$34.28M | -$25.10M | -$28.58M | -$31.69M | -$26.90M | -$27.07M | -$24.60M | -$25.99M | -$22.73M |
| Income tax | - | - | - | $0 | $0 | $0 | $0 | $0 | $0 | $232.0K | $0 | $0 |
| Net income | -$27.70M | -$32.48M | -$23.63M | -$29.67M | -$20.15M | -$25.34M | -$28.54M | -$23.18M | -$23.16M | -$19.95M | -$22.74M | -$19.37M |
| EPS, basic | -$0.36 | -$0.49 | -$0.38 | -$0.45 | -$0.32 | -$0.49 | -$0.57 | -$0.46 | -$0.48 | -$0.41 | -$0.54 | - |
| EPS, diluted | -$0.36 | -$0.49 | -$0.38 | -$0.45 | -$0.32 | -$0.49 | -$0.57 | -$0.46 | -$0.48 | -$0.41 | -$0.54 | - |
| Diluted shares | 78.0M | 66.2M | 62.8M | - | 62.1M | 52.1M | 50.1M | - | 48.3M | 48.1M | 42.0M | - |
Balance sheet
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $151.67M | $135.50M | $132.18M | $98.90M | $101.73M | $119.44M | $101.70M | $124.17M | $100.62M | $96.87M | $149.16M | $100.19M |
| Short-term investments | $732.68M | $759.65M | $320.22M | $363.73M | $375.83M | $371.07M | $187.85M | $189.32M | $191.21M | $215.52M | $171.34M | $153.01M |
| Current assets | $894.76M | $907.34M | $463.14M | $474.88M | $482.68M | $495.62M | $294.32M | $318.13M | $297.00M | $318.13M | $337.20M | $266.15M |
| Total assets | $897.23M | $910.22M | $464.85M | $476.17M | $490.88M | $503.89M | $302.57M | $325.76M | $305.43M | $327.04M | $342.78M | $271.87M |
| Current liabilities | $19.47M | $14.16M | $11.49M | $16.57M | $14.65M | $15.21M | $13.97M | $15.91M | $17.03M | $22.11M | $25.03M | $25.89M |
| Total liabilities | $20.28M | $15.07M | $11.49M | $16.57M | $14.75M | $15.41M | $14.27M | $15.91M | $17.03M | $22.11M | $25.07M | $25.96M |
| Shareholders' equity | $876.95M | $895.15M | $453.37M | $459.60M | $476.12M | $488.47M | $288.30M | $309.85M | $288.40M | $304.93M | $317.71M | $245.91M |
Cash flow
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -$12.55M | -$18.53M | -$19.29M | -$15.84M | -$13.28M | -$17.06M | -$24.13M | -$17.20M | -$12.19M | -$20.43M | -$23.36M | -$12.48M |
| Capital expenditures | $94.0K | $99.0K | $0 | $0 | -$1.0K | $139.0K | $20.0K | $0 | $22.0K | $2.0K | $20.0K | $14.0K |
| Free cash flow | -$12.65M | -$18.63M | -$19.29M | -$15.84M | -$13.28M | -$17.20M | -$24.15M | -$17.20M | -$12.21M | -$20.44M | -$23.38M | -$12.50M |
| Investing cash flow | $26.33M | -$441.57M | $42.53M | $12.38M | -$4.06M | -$183.59M | $1.43M | $727.0K | $14.83M | -$33.66M | -$17.89M | $38.69M |
| Financing cash flow | $2.39M | $463.42M | $10.05M | $623.0K | -$368.0K | $218.38M | $234.0K | $39.97M | $1.12M | $1.81M | $90.27M | $90.0K |
| Stock-based compensation | $8.06M | $13.91M | $7.40M | $12.31M | $7.18M | $7.72M | $6.80M | $5.34M | $5.18M | $5.14M | $4.51M | $3.06M |
| Depreciation and amortization | $13.0K | $7.0K | $14.0K | $83.0K | $62.0K | $81.0K | $74.0K | $63.0K | $80.0K | $79.0K | $79.0K | $80.0K |
Key ratios
| Line item | Sep 30, 2026 | Jun 30, 2026 | Mar 31, 2026 | Dec 31, 2025 | Sep 30, 2025 | Jun 30, 2025 | Mar 31, 2025 | Dec 31, 2024 | Sep 30, 2024 | Jun 30, 2024 | Mar 31, 2024 | Dec 31, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current ratio | 45.95 | 64.07 | 40.32 | 28.66 | 32.95 | 32.58 | 21.06 | 19.99 | 17.44 | 14.39 | 13.47 | 10.28 |
Source: XBRL data Enliven Therapeutics Inc. files with the SEC, latest filing dated Nov 5, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures are as filed. The filings show no stock split in these periods.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
ELVN peers
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| ELVN | - | - | -$113.48M | - | $3.77B |
| LLY | $86.46B | +45.5% | $27.58B | 31.9% | $1.35T |
| JNJ | $99.33B | +7.8% | $16.09B | 16.2% | $675.92B |
| ABBV | $66.01B | +10.7% | $10.34B | 15.7% | $519.48B |
| MRK | $67.38B | +4.9% | $2.45B | 3.6% | $364.98B |
| NVS | $54.53B | +8.4% | $13.98B | 25.6% | $311.52B |
| AZN | $58.74B | +8.6% | $10.22B | 17.4% | $289.61B |
| ABT | $48.23B | +10.0% | $4.70B | 9.7% | $191.31B |
| NVO | DKK 309.06B | +6.4% | DKK 102.43B | 33.1% | $180.22B |
ELVN FAQ
6 questionsIs ELVN profitable?
No. Enliven Therapeutics Inc. reported a net loss of $113.48M for the twelve months ended Sep 30, 2026.How much cash and debt does ELVN have?
Enliven Therapeutics Inc. reported $151.67M in cash and cash equivalents on its most recent balance sheet in SEC filings.What is ELVN free cash flow?
Enliven Therapeutics Inc. generated -$66.41M of free cash flow for the twelve months ended Sep 30, 2026, which is operating cash flow of -$66.22M less capital expenditures.What is ELVN earnings per share?
Diluted earnings per share were -$1.68 for the twelve months ended Sep 30, 2026, from SEC filings, restated for any stock split those filings show.When did ELVN last report financial results?
The latest statements here come from Enliven Therapeutics Inc.'s 10-Q filed on Nov 5, 2026, covering the period ended Sep 30, 2026.Where does this ELVN financial data come from?
Quantisnow builds these statements from the structured XBRL data Enliven Therapeutics Inc. files with the SEC. It is provided for information only and is not investment advice.